Arvinas Inc. (NASDAQ: ARVN) reported positive results from a phase 1 clinical trial of ARV-102, an experimental drug for Parkinson's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE